

# Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for *FLT3*-mutated acute myeloid leukemia patients – Czech center experience

Barbora Weinbergerová,<sup>1,2+</sup> Martin Čerňan,<sup>3</sup> Tomáš Kabut,<sup>1,2</sup> Lukáš Semerád,<sup>1,2</sup> Natália Podstavková,<sup>1,2</sup> Tomáš Szotkowski,<sup>3</sup> Ivana Ježíšková<sup>1,2</sup> and Jiří Mayer<sup>1,2+</sup>

<sup>1</sup>Department of Internal Medicine, Hematology and Oncology, Masaryk University, Brno; <sup>2</sup>Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno and <sup>3</sup>Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic

*+BW and JM contributed equally to this work.*

Correspondence:

B. WEINBERGEROVÁ - Weinbergerova.Barbora@fnbrno.cz

<https://doi.org/10.3324/haematol.2022.282263>

**Supplemental table 1.** Enrolled Study Patient Characteristics at the Time of AML Diagnosis.

Pt. No.	Age/ Gender	ECOG	AML (WHO 2016)	Genetics	<i>FLT3</i> Subtype	<i>FLT3</i> Allelic Ratio	ELN Risk 2017
1	57/M	0	With recurrent genetic abnormalities	<i>NPM1</i>	ITD	Low (<0.5)	Favourable
2	27/F	0	With recurrent genetic abnormalities	<i>NPM1</i>	ITD	Low (<0.5)	Favourable
3	52/M	1	With recurrent genetic abnormalities	<i>NPM1</i>	TKD	-	Favourable
4	30/M	2	NOS (M2)	-	ITD	High ( $\geq 0.5$ )	Adverse
5	26/M	1	With recurrent genetic abnormalities	<i>RUNX1::RUNX1T1</i>	TKD	-	Favourable
6	41/M	2	With recurrent genetic abnormalities	<i>RUNX1</i>	ITD / TKD	Low (<0.5)	Adverse
7	61/M	0	Therapy-related	-	ITD	High ( $\geq 0.5$ )	Adverse
8	49/F	1	With recurrent genetic abnormalities	<i>NPM1</i>	ITD	Low (<0.5)	Favourable
9	32/F	1	With recurrent genetic abnormalities	<i>NPM1</i>	TKD	-	Favourable
10	54/M	1	NOS (M4)	-	ITD / TKD	Low (<0.5)	Intermediate
11	44/F	1	Therapy-related	<i>NPM1</i>	ITD	Low (<0.5)	Favourable

Abbreviations: AML – Acute Myeloid Leukemia; M – men; F – female; WHO – World Health Organization; NOS – Not Otherwise Specified; ITD – Internal Tandem Duplication; TKD – Tyrosine Kinase Domain; ELN – European Leukemia Net

**Supplemental table 2.** Patient Treatment Outcomes and Toxicity following GO+MIDO+IC Regimen.

1 <sup>st</sup> Cycle of GO+MIDO+IC Reason for GO discontinuation	2 <sup>nd</sup> Cycle of GO+MIDO+IC		3 <sup>rd</sup> Cycle of GO+MIDO+IC Efficacy	Subsequent Therapy	Final Efficacy	Efficacy at last FU	Status at last FU
	Efficacy	Reason for GO discontinuation					
Infection				4cy IDAC+MIDO	CR <sub>mol</sub> -	R <sub>I</sub> <sub>mol</sub>	Alive
NA	CR <sub>mol</sub> +	NA	ND	1cy IDAC+MIDO	CR <sub>mol</sub> -	R <sub>h</sub> <sub>cm</sub>	Alive
NA	ND	NA	CR <sub>mol</sub> +	2cy IDAC+MIDO	CR <sub>mol</sub> -	CR <sub>mol</sub> -	Alive
Treatment failure				1cy FLAG / 1cy HDAC / Allo-HSCT	CR <sup>†</sup>	CR <sup>†</sup>	Alive
NA <sup>#</sup>					CR <sup>*</sup>	CR <sup>*</sup>	Alive
NA	CR <sub>mol</sub> -	Allo-HSCT		Allo-HSCT	CR <sub>mol</sub> -	R <sub>I</sub> <sub>mol</sub>	Alive
NA	CR <sub>mol</sub> +	NA	CR <sub>mol</sub> +	Gilteritinib / Allo-HSCT	CR <sub>mol</sub> -	CR <sub>mol</sub> -	Dead
NA	CR <sub>mol</sub> +	NA	CR <sub>mol</sub> -		CR <sub>mol</sub> -	CR <sub>mol</sub> -	Alive
NA	CR <sub>mol</sub> +	Allo-HSCT		Allo-HSCT	CR <sub>mol</sub> -	CR <sub>mol</sub> -	Alive
SOS				1cy HDAC+MIDO	CR <sub>mol</sub> -	CR <sub>mol</sub> -	Alive
NA <sup>#</sup>					CR <sup>*</sup>	CR <sup>*</sup>	Alive

	<b>Efficacy</b>	CR <sub>mol-</sub>	CR <sub>mol+</sub>	CR <sub>mol+</sub>	RD	CR*	CR <sub>mol-</sub>	CR <sub>mol+</sub>	CR <sub>mol+</sub>	CR <sub>mol+</sub>	CR <sub>mol-</sub>	CR*
<b>Pt. No.</b>		1	2	3	4	5	6	7	8	9	10	11

Abbreviations: GO+MIDO+IC – Gemtuzumab

Ozogamicin+Midostaurin+Intensive Chemotherapy; cy - Cycle;

CR – Complete Remission; CR<sub>mol-</sub> – Molecular Complete

Remission; CR<sub>mol+</sub> – Complete Remission with Positive

Molecular Minimal Residual Disease; RD – Refractory Disease;

FU – Follow-up; NA – Not Applicable; SOS – Sinusoidal

Obstruction Syndrome; ND – Not Done; R1<sub>mol</sub> – First Molecular

Relaps; R1<sub>hem</sub> – First Hematological Relaps; Allo-HSCT –

Allogeneic Hematopoietic Stem Cell Transplantation; IDAC –

Intermediate Dose of Cytarabine; HDAC – High Dose of

Cytarabine; FLAG – Fludarabine+Cytarabin+G-CSF

\* - Molecular MRD data were not available at the time of analysis.

¶ - Molecular MRD cannot be measured.

# - Unavailable data owing to short follow-up